Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
0.8600
-0.0298 (-3.35%)
Oct 29, 2026, 4:00 PM EDT - Market closed
Pliant Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
49
Market Cap
53.25M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.58M | -8.11M | -83.69% |
| Dec 31, 2022 | 9.69M | 2.11M | 27.91% |
| Dec 31, 2021 | 7.57M | -34.25M | -81.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| Werewolf Therapeutics | 21.00M |
| Alps Group | 3.74M |
| Connect Biopharma Holdings | 2.95M |
| Hyperion DeFi | 1.40M |
| Clene | 197.00K |
| iBio, Inc. | 100.00K |
PLRX News
- 16 hours ago - Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - GlobeNewsWire
- 10 days ago - Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA) - GlobeNewsWire
- 10 days ago - Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026 - GlobeNewsWire
- 4 weeks ago - Pliant Therapeutics appoints David Raben as Chief Medical Officer - TheFly
- 4 weeks ago - Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095 - TheFly
- 2 months ago - Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - GlobeNewsWire
- 2 months ago - Pliant Therapeutics reports Q2 EPS (36c), consensus (34c) - TheFly